anabolizmin
Anabolizmin is a synthetic anabolic agent that was first identified in 2012 during a series of screening studies for new performance-enhancing substances. Chemically, it is a progestogen‑derived compound with high affinity for the androgen receptor, and it possesses a unique hydroxyl group that enhances its metabolic stability. Early in vitro studies showed that anabolizmin promotes protein synthesis in skeletal muscle cells at lower doses than many conventional anabolic steroids, which led to interest from both medical researchers and sporting bodies.
The compound has been used experimentally in small clinical trials involving patients with muscle wasting disorders.
Health authorities have approached anabolizmin with caution. In 2015, the World Anti‑Doping Agency classified it as
Current scientific literature indicates that further pharmacokinetic and long‑term safety studies are necessary before anabolizmin can